Amplia Therapeutics Limited's (ASX:ATX) Dr John Lambert speaks to Proactive's Andrew Scott following the news they've begun dosing the first volunteers in its Phase 1 clinical trial of AMP945. The molecule's being developed for difficult-to-treat cancers and fibrotic diseases. Amplia expects to complete dosing in the trial during the first half of next year, which should allow reporting of top-line results around the middle of 2021.
viewAmplia Therapeutics Ltd
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Quick facts: Amplia Therapeutics Ltd
Price: 0.295 AUD
ASX:ATX
Market: ASX
Market Cap: $31.78 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Amplia Therapeutics Ltd named herein, including the promotion by the Company of Amplia Therapeutics Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Mining
Mako Gold increases Côte d’lvoire footprint on grant of Ouangolodougou...
6 days, 20 hours ago
Health
Imugene receives approval for phase I clinical trial of new checkpoint...
6 days, 17 hours ago
Energy
88 Energy says it is temporarily minimising spending in Alaska as it awaits...
5 days, 10 hours ago
